Mainz Biomed (MYNZ) Stock Price, News & Analysis

Company Overview

Mainz Biomed AG is a molecular diagnostics company headquartered in Mainz, Germany, specializing in epigenetics-based tests for the early detection of cancer. The company develops proprietary assays that analyze DNA methylation patterns and other epigenetic biomarkers to identify malignancies at a stage when treatment outcomes are most favorable. Mainz Biomed’s technology platform is designed to offer non-invasive, easy-to-use screening solutions that can be deployed both in laboratory settings and at point of care.

The company’s flagship product, ColoAlert®, is a stool-based colorectal cancer screening test that combines DNA methylation markers with bacterial gene targets to improve sensitivity and specificity for detecting advanced adenomas and early-stage colorectal cancer. ColoAlert® has received CE marking for commercialization in Europe and is part of Mainz Biomed’s strategy to address gaps in current screening programmes by offering an alternative to traditional colonoscopy and immunochemical fecal occult blood tests.

Founded as a spin-off from the Johannes Gutenberg University Mainz, Mainz Biomed has leveraged academic research in epigenetics to build a clinical pipeline focused on gastrointestinal cancers. The firm has established partnerships with clinical research centres and diagnostic laboratories across Europe, and it is conducting studies to support regulatory submissions in the United States. Through these collaborations, Mainz Biomed aims to validate its assays in diverse patient populations and support the integration of epigenetic testing into standard screening protocols.

Led by a management team with deep experience in biotechnology, molecular diagnostics and regulatory affairs, Mainz Biomed continues to expand its product portfolio and broaden its geographic footprint. The company is pursuing additional indications beyond colorectal cancer and is investing in research and development to refine its platform for the early detection of other tumor types. As it advances clinical validation and navigates regulatory pathways, Mainz Biomed seeks to establish itself as a leader in epigenetic diagnostics and preventive oncology.

Key Stats

• Today's Range: $1.95 to $2.21
• 50-Day Range: $0.32 to $3.56
• 52-Week Range: $0.55 to $4.43
• Volume: 1.92 million shs
• Average Volume: 371,589 shs
• Market Capitalization: $19.93 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Reduce

Mainz Biomed Stock Analysis - MarketRank™

Mainz Biomed scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.8 / 5
• Analyst Rating: Reduce

Consensus Rating

Mainz Biomed has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Mainz Biomed has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Mainz Biomed are expected to grow in the coming year, from ($23.60) to ($9.20) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Mainz Biomed is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mainz Biomed is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Mainz Biomed has a P/B Ratio of 0.84. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for MYNZ.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mainz Biomed does not currently pay a dividend.

Dividend Growth

Mainz Biomed does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Mainz Biomed this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Mainz Biomed insiders have not sold or bought any company stock.

Percentage Held by Insiders

18.20% of the stock of Mainz Biomed is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Mainz Biomed has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/15/2023
• Today: 6/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MYNZ
• CIK: 1874252
• Web: mainzbiomed.com
• Phone: 49-6131-554-2860
• Fax: N/A
• Employees: 30
• Year Founded: 2021

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.44
• Current Ratio: 0.52
• Quick Ratio: 0.43

Sales & Book Value

• Annual Sales: $659.94 thousand
• Price / Sales: 30.20
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.61 per share
• Price / Book: 0.84

Miscellaneous

• Outstanding Shares: 9,060,000
• Free Float: 7,411,000
• Market Cap: $19.93 million
• Optionable: Not Optionable
• Beta: 0.31